ReviewNature reviews. Urology2016
The endocannabinoid system - a target for the treatment of LUTS?
Review in Nature reviews. Urology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 36 citations in OpenAlex.
- The significance of endocannabinoid receptors and endocannabinoids in the lower urinary and genital tract.World journal of urology · 2025Review
- Cannabis Use is Associated With Lower Urinary Tract Symptoms in Pediatric Patients-A Large Claims Database Study.Urology · 2025Article
- The Impact of a Healthy Lifestyle on Lower Urinary Tract Symptoms and Erectile Function: A Prospective Study.Healthcare (Basel, Switzerland) · 2025Article
- Aging and urinary control: Alterations in the brain-bladder axis.Aging cell · 2023Review
- Cannabidiol as a Promising Therapeutic Option in IC/BPS: In Vitro Evaluation of Its Protective Effects against Inflammation and Oxidative Stress.International journal of molecular sciences · 2023Article
- Palmitoylethanolamide and Related ALIAmides for Small Animal Health: State of the Art.Biomolecules · 2022Review
- Components of the Endogenous Cannabinoid System as Potential Biomarkers for Interstitial Cystitis/Bladder Pain Syndrome.Diagnostics (Basel, Switzerland) · 2021Review
- A Systematic Review of Therapeutic Approaches Used in Experimental Models of Interstitial Cystitis/Bladder Pain Syndrome.Biomedicines · 2021Review
- Endocannabinoids in Bladder Sensory Mechanisms in Health and Diseases.Frontiers in pharmacology · 2021Review
- Lower urinary tract symptoms in men: challenges to early hospital presentation in a resource-poor health system.BMC urology · 2020Article
- Emerging drugs to target lower urinary tract symptomatology (LUTS)/benign prostatic hyperplasia (BPH): focus on the prostate.World journal of urology · 2020Review
- Mechanisms Underlying Overactive Bladder and Interstitial Cystitis/Painful Bladder Syndrome.Frontiers in neuroscience · 2018Review
- Review
- Role of cannabinoid receptor type 1 in tibial and pudendal neuromodulation of bladder overactivity in cats.American journal of physiology. Renal physiology · 2017Article
- Recent advances in pharmacological management of urinary incontinence.F1000Research · 2017Review
Corrections and comments
- Commented on by
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lower urinary tract symptoms (LUTS) are common in all age groups and both sexes, resulting in tremendous personal suffering and a substantial burden to society. Antimuscarinic drugs are the mainstay of symptom management in patients with LUTS, although their clinical utility is limited by the high prevalence of adverse effects, which often limit patients' long-term adherence to these agents. Data from controversial studies in the 1990s revealed the positive effects of marijuana-based compounds on LUTS, and sparked an interest in the possibility of treating bladder disorders with cannabis. Increased understanding of cannabinoid receptor pharmacology and the discovery of endogenous ligands of these receptors has prompted debate and further research into the clinical utility of exogenous cannabinoid receptor agonists relative to the unwanted psychotropic effects of these agents. Currently, the endocannabinoid system is considered as a potential drug target for pharmacological management of LUTS, with a more favourable adverse event profile than antimuscarinic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.